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and increased mortality, after adjusting for initial stroke severity, has been shown in several observational cohort studies. These findings suggest a possible deleterious effect of elevated blood glucose beyond it being a simple marker of the cerebral injury. 6, 7 The effects of elevated blood glucose have been observed in animal models of stroke. In experimental models of either global or focal ischemia, hyperglycemia preceding stroke onset was associated with increased cerebral damage and worse functional outcome. [8] [9] [10] Pathological processes documented in these hyperglycemic animals include augmented intracellular acidosis and increased neuronal cell death, 11 worsened cerebral edema, 8, 12 and an increased tendency for secondary hemorrhage. Reversal of initial hyperglycemia has been shown to limit the extent of cerebral infarction in animal models. 13 Elevated glucose has also been associated with increased mortality and worse functional outcome in human studies of patients with acute myocardial infarction and patients in intensive care. [14] [15] [16] The treatment of elevated blood glucose in these medical settings has been associated with lower mortality and morbidity in several studies. [17] [18] [19] A meta-analysis of nine studies of patients with myocardial infarction showed an overall 28% risk reduction for in-hospital mortality (odds ratio 0.72, 95% CI 0.57 -0.90, p = 0.004). 20 In ICU patients, an overall 15% decrease in mortality has been shown. 19 In stroke patients, the Glucose in Stroke Trial (GIST-UK) was the first randomized trial of glucose lowering using an intravenous insulin infusion compared to a normal saline control infusion. 21 This study of 933 patients showed no difference in 90-day mortality or functional disability in stroke patients treated with insulin infusion compared to controls. However, the study did not reach its recruitment target and was likely underpowered to demonstrate a difference between the treatment and control groups. Moreover, GIST study patients had only modestly elevated glucose levels at enrollment (median 7.6 mmol/l, interquartile range 6.7 -9.0 mmol/l) and glucose spontaneously decreased in the control group to within the study target level over 24 hours, making it plausible that a true difference between the treatment and control groups was simply not demonstrated. Other smaller studies have shown safety of glucose lowering in stroke patients, but none have evaluated patients for outcomes like mortality or functional disability.
Currently, Canadian practice guidelines recommend that blood glucose be evaluated and closely monitored in patients following stroke. 22 These guidelines provide no specific direction to physicians regarding the level above which they might consider treating glucose or what glucose level to target if treatment is initiated. Also, there is no guidance as to which treatment strategies are optimal. Practice guidelines from the American Stroke Association make a stronger statement to consider initiating treatment of glucose above levels of > 7.8 to 10.3 mmol/l in patients with ischemic and hemorrhagic stroke, though the evidence supporting these statements is limited. 23, 24 We set out to examine the current care practices of physicians in Ontario in the management of hyperglycemia in patients with stroke using a self-report questionnaire. The main goal of this study was to determine whether there are differences in management strategies between different physician specialty groups involved in the care of stroke patients.
METHODS

Physician Sample
A list of physicians was generated using the Canadian Medical Directory. The main selection criterion for the survey sample was a hospital-affiliated medical practice based in Ontario. Both English and French speaking physicians were included. We targeted the following specialties: emergency medicine, family medicine, internal medicine, intensive care, and neurology.
Survey Development
A questionnaire was created as a self-report survey of physician care practices for glucose management in stroke patients (see Appendix). We obtained demographic information pertaining to physicians' work environments and clinical practice details, and inquired about their involvement in providing care to stroke patients. Only physicians who reported providing care to stroke patients completed the remainder of the survey questions regarding their understanding of the impact of hyperglycemia in stroke patients and their knowledge of management recommendations for hyperglycemia in stroke patients based on existing evidence. The survey also examined in detail how physicians who did provide care for stroke patients approached the management of glucose in stroke patients based on specific patient scenarios, including stroke patients with no history of diabetes or diet-controlled diabetes (Scenario 1), patients on oral hypoglycemic agents for previously diagnosed diabetes (Scenario 2), and patients on subcutaneous insulin for previously diagnosed diabetes (Scenario 3). For Scenario 1, the management choices included: no treatment, oral hypoglycemic agents, sub-cutaneous insulin, insulin infusion, or unsure. For Scenario 2, management choices included: continue same medications, increase oral agent doses, subcutaneous insulin, insulin infusion, or unsure. For Scenario 3, management choices included: continue same subcutaneous insulin dose, increase subcutaneous insulin dose, insulin infusion, other, or unsure. Insulin infusion was considered the most aggressive form of glucose therapy. The proportion of physicians choosing a specific therapy was determined across the range of glucose values above 6.0 mmol/l.
The questionnaire was mailed out to the entire physician sample, but a web-based version was also created to allow physicians to complete the survey online. A cover letter explained the purpose of the study and provided the web address where the survey could be accessed online. Usual methods to enhance survey response rate were used (designing a clear and concise survey, self-addressed return envelopes, reminder sent to physicians). 25, 26 
Statistical Analysis
The proportion of physicians responding to the survey was calculated. Baseline characteristics for non-responders were compared to responders (including physician specialty group, language, and location of medical practice). Of the returned surveys, baseline characteristics of physicians who did and did not treat stroke were compared. The proportion of physicians who responded to each survey question choice regarding the treatment of glucose was determined. Chi-square analysis was used for comparisons between physician groups. A mean treatment aggressiveness score was derived by designating a numeric value for each possible treatment selection in the survey questions pertaining to glucose management (see Appendix, questions 14 -16) and calculating a mean for each physician specialty group. For example, responses for question 14 were designated as "no treatment" = 0, "oral agents" = 1, "insulin subcutaneously" = 2, and "insulin intravenously" = 3. Mean scores were represented graphically to provide a visual depiction of any differences in management practices between specialty groups.
Ethics and Confidentiality
Consent to participate in the study was implied if the physician completed and returned the survey; this was explained in the cover letter. Identifying information was not included on the returned surveys to maintain confidentiality of respondents. This study was approved by the Research Ethics Board of the University Health Network.
RESULTS
The survey was mailed out to 2,280 physicians across the province of Ontario. Survey responses were received from 610 physicians (26.8%). Two returned surveys were blank; 608 surveys were included in the study. Generally, there was a < 6% non-response rate for individual survey questions. Based on postal codes, physician respondents were equally represented across all geographic regions of Ontario. 27 Comparing respondents to non-respondents, there was no difference in response rate for certified specialists versus general practitioners. However, of the total surveys sent out to each physician group, there was a lower proportion of emergency physicians who responded versus other groups (p = 0.003). Other nonrespondents had specialty designations in surgery, anesthesia, pathology and laboratory medicine, and sub-specialties in medicine.
Demographics of Respondents
In the total group of respondents, 72.2% were male and 27.7% were female. Fifty-one percent of male physicians versus 39.4% of female physicians reported managing stroke patients (p = 0.018). Overall, 278 (45.7%) respondents reported providing care to stroke patients. A majority of respondents reported practicing in an academic centre, representing 53.8% of the physician sample that manage stroke patients. The breakdown of physician respondents by specialty is shown in Table 1 . Emergency physicians, general internists, and neurologists were more likely to manage stroke patients compared to other specialists (p < 0.0001). Neurologists were more likely to treat > 20 stroke patients per month, compared to over 58% of other specialty physicians who treated only one to five per month (p < 0.0001). Intensive care specialists (81.8%) and neurologists (76.7%) most frequently reported having a stroke unit (either a dedicated stroke unit or a nursing unit with clustering of stroke patients) in their institution. A multidisciplinary stroke team was reported to be available by 86% of intensive care specialists, 77% of neurologists, 65% of emergency physicians, 60% of general internists, and 33% of family physicians. The majority of physicians had a stroke expert at their facility, though only 16.7% of family physicians reported having access to a stroke expert.
Regarding physician awareness of general practice guidelines for the management of hyperglycemia, approximately one-third to one-half of all physicians acknowledged being aware of such guidelines. Fifty percent of intensive care specialists reported having a specific management protocol for patients with elevated glucose, whereas less than 35% of the other specialty physicians were aware of such a protocol at their institution. Of those physicians who either were aware of a practice guideline or had a specific hospital protocol, 67% of intensive care specialists, 67% of family physicians, 52% of neurologists, 42% of emergency physicians, and 33% of general internists stated that they based their management of glucose in stroke patients on such recommendations.
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Management of Glucose in Stroke Patients
Physicians were more aggressive in the treatment reported with increasing levels of initial glucose in the patient scenarios. However, even in patients without a history of diabetes, 9.3% of physicians reported they would begin an insulin infusion for an initial glucose 8.1 -10.0 mmol/l ( Table 2) . This finding was similar in patients with diabetes controlled with oral hypoglycemic agents (Table 3 ). In stroke patients with diabetes previously treated with subcutaneous insulin, 12.2% of physicians reported beginning an insulin infusion for glucose 8.1 -10.0 mmol/l and 20% reported beginning insulin infusion for glucose 10.1 -12.0 mmol/l (Table 4) .
When comparing individual physician specialty groups, there was no significant difference in treatment for glucose 6.0 -8.0 mmol/l (p = 0.103) in stroke patients with no history of diabetes (or diet-controlled diabetes). In this patient group, most physicians would not initiate treatment, though 20% of intensive care specialists reported using an insulin infusion. For glucose 8.1 -10.0 mmol/l, 55% of intensive care specialists reported treating with an insulin infusion and another 32% reported beginning subcutaneous insulin. However, in the other physician groups, 50% of family physicians, internists, and neurologists reported they would not initiate treatment for this patient group and 77% of emergency physicians reported the same (p < 0.0001). Differences in glucose management in stroke patients with no history of diabetes (or diet-controlled diabetes) were also observed for glucose 10.1 -12.0 mmol/l, 12.1 -16.0 mmol/l, and > 16.0 mmol/l. Intensive care specialists were more likely to report using insulin infusion throughout the range of glucose values and emergency physicians were least likely to choose this management strategy (p < 0.0001). Figure 1 illustrates the differences in glucose treatment between physician specialty groups.
In stroke patients with diabetes previously controlled with oral hypoglycemic agents, for glucose 6.0 -8.0 mmol/l, intensive care specialists reported using insulin infusion 35% of the time, whereas all other specialties reported continuing the same oral medications in over 70% of patients (p < 0.0001). This trend continued throughout all glucose ranges, including glucose > 16.0 mmol/l where 96% of intensive care specialists, 46% of general internists, 42% of neurologists, 33% of emergency physicians, and 17% of family physicians reported using insulin infusion (p = 0.054) (Figure 2) .
Finally, for stroke patients with diabetes previously controlled with subcutaneous insulin, differences in the management persisted between physician groups (Figure 3) . Intensive care specialists remained the most aggressive in managing glucose; this group reported the use of insulin infusion in 40% of patients with glucose between 6.0 -8.0 mmol/l and in a higher proportion of patients with higher glucose levels. For the lowest glucose range, other physician groups reported using insulin infusion in only 10% of patients; more often they reported increased use of subcutaneous insulin to manage glucose across all ranges.
Examining target blood glucose levels when treatment was initiated, 16.6% of physicians targeted glucose 4.0 -6.0 mmol/l, 52% targeted 6.1 -8.0 mmol/l, 13.6% targeted 8.1 -12.0 mmol/l, and 0.8% targeted 12.1 -15.0 mmol/l. Almost 10% of physicians chose a range other than those provided and 7.5% were unsure as to their target glucose level. Comparing specialty groups, over 40% of physicians in any group reported a target glucose range of 6.1 -8.0 mmol/l, whereas 32% of intensive care specialists, 17.5% of neurologists, 13% of general internists, 14% of emergency physicians, and 0% of family physicians reported a target of 4.0 -6.0 mmol/l (p = 0.026). Overall, 203 (77.2%) physicians reported having a goal of achieving target glucose within 24 hours of patient presentation to hospital and only 34 (12.9%) reported using a time frame of > 24 hours. Comparing specialties, 100% of intensivists, 86.4% of neurologists, 80% of family physicians, 75.8% of emergency physicians, and 65.4% general internists would treat glucose to target within 24 hours of patient presentation (p < 0.0001). There were 25 (9.5%) physicians overall who were unsure within which time frame to lower glucose in stroke patients; 16 (64%) were emergency physicians.
DISCUSSION
In this survey of Ontario physicians, we found marked variations in the reported management of glucose in stroke patients. As well, some physicians reported treating glucose in Table 4 : Treatment of stroke patients with diabetes previously managed with subcutaneous insulin * Glucose units in mmol/l; SC ins=subcutaneous insulin stroke patients at relatively low initial glucose levels. Almost 10% of physicians reported they would begin an insulin infusion for an initial glucose 8.1 -10.0 mmol/l in stroke patients with no diabetes; physicians were more aggressive in treating glucose at higher initial glucose levels and in patients with diabetes. When physicians initiated treatment for glucose, nearly 70% had a glucose target < 8.0 mmol/l, including over 15% who targeted glucose 4.0 -6.0 mmol/l, and nearly 80% reported having a goal of achieving target glucose within 24 hours of patient presentation.
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We identified significant differences in the approach to the management of glucose in stroke patients between physician specialty groups. Intensive care specialists were most aggressive in treating glucose, including treating patients with no history of diabetes or diet controlled diabetes who present to hospital with glucose 6.0 -10.0 mmol/l. This finding may relate to prior literature supporting aggressive glucose lowering in intensive care patients, despite the fact that these studies were not conducted in the stroke patient population. Another possible explanation for the more aggressive glucose management by intensivists may relate to staffing and other resources necessary to support using insulin infusion that are available in the ICU. Other physician specialty services care for stroke patients on regular nursing units where glucose management with intravenous insulin may not be practical. Also, emergency physicians often reported deferring glucose management to the internist or consulting specialist, as care would ultimately be transferred to an inpatient service provider within a short time frame from hospital presentation. Both emergency physicians and family physicians also reported that a lack of certainty regarding any guidelines for the management of glucose in stroke patients was a reason for not initiating treatment.
Currently, in stroke patients, optimal blood glucose target levels and the time frame within which targets should be attained are still uncertain. Though the GIST-UK study did not demonstrate a benefit with glucose treatment, limitations in the methodology may have contributed to a negative result. Future studies should carefully choose which stroke patients to include and consider alternative insulin protocols to further evaluate the potential benefits of glucose lowering in stroke patients. Results of our study, showing variability in the current management of glucose in stroke patients and particularly aggressive glucose lowering by some physicians, highlight an urgent need for further studies to clarify the importance of glucose lowering in this patient population. At present, caution should still be exercised to avoid overly aggressive or rapid correction of hyperglycemia, particularly given the deleterious effects of hypoglycemia in stroke patients.
Limitations inherent to surveys may have affected our study results. Responder bias is a potential concern relating to the uncertainty about potential differences in responders compared to the likely responses of non-responders. 28 We found no significant differences in the baseline demographics of survey responders versus non-responders, though the management practices of physicians in the non-responder group remain unknown. As well, a large proportion of non-responders had specialty designations in the Canadian Medical Directory database that would not likely be involved in the care of stroke patients in their routine practice. Thus, the higher rate of nonresponders also reflects a limitation in the specificity of physician list generation using this database. Nevertheless, the low survey response rate may affect the generalisability of our results. Regarding physician responses, social acceptability bias may be an issue if physicians responded with what they thought would be "correct" responses for treatment questions and not based on their actual practice. 28 Another limitation of the analysis was that differences in the management of glucose between physician groups were not adjusted for baseline physician and clinical practice characteristics and as such, we cannot make specific conclusions as to why differences exist in these care practices. This limitation would be particularly relevant to the comparison of intensive care specialists and other physician groups, as care practices are possibly guided by resource availability. In addition, though intensive care specialists were shown in this study to treat glucose more aggressively than other specialty groups, overall this physician group would not be involved in the care of the majority of stroke patients in the general population and so the differences in care practices highlighted in this study may be an overestimate. Though our overall sample size was reasonable, there were fewer respondents in certain physician specialty groups and for this reason, we were not able to examine potential differences in glucose management in stroke patients within each physician specialty group that may have also been informative.
We report a wide variability in the aggressiveness of glucose management in stroke patients by different physician specialty groups. Though the specific reasons for these differences need to be further evaluated, the results of our study likely reflect a lack of evidence available to guide physicians in managing hyperglycemia in this setting. Our study highlights an important THE CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES 578 gap in current knowledge and in recommendations for stroke patient care that must be addressed to ensure optimal patient outcomes. Further randomized trials of glucose treatment in stroke patients must be pursued to provide a better understanding of this important issue in stroke care.
